Filed
Pursuant to Rule 424(b)(5)
Registration
No. 333-239890
PROSPECTUS
SUPPLEMENT
(to
the Prospectus dated July 23, 2020)
4,761,905
Shares of Common Stock
We
are offering 4,761,905 shares of our common stock, par value $0.00001 per share, at an offering price of $6.30 per share.
Our
common stock is listed on The Nasdaq Global Market, or Nasdaq, under the symbol “PSTI” and on the Tel Aviv Stock Exchange,
or TASE, under the symbol “PSTI.” On February 1, 2021, the last reported sale price for our common stock on Nasdaq
was $7.46 per share.
We have retained A.G.P./Alliance Global Partners as placement agent
in connection with this offering. The placement agent has agreed to use its reasonable best efforts to sell the securities offered
by this prospectus supplement and the accompanying prospectus. The placement agent is not purchasing or selling any shares offered
by this prospectus supplement and the accompanying prospectus. See “Plan of Distribution” beginning on page S-6 of
this prospectus supplement for more information regarding these arrangements.
|
|
Per Share
|
|
|
Total
|
|
Public offering price
|
|
$
|
6.30
|
|
|
$
|
30,000,000
|
|
Placement agent’s
fees (6%)(1)
|
|
$
|
0.378
|
|
|
$
|
1,800,000
|
|
Proceeds to us, before expenses
|
|
$
|
5.922
|
|
|
$
|
28,200,000
|
|
|
(1)
|
We have agreed to pay the placement agent an aggregate cash placement fee equal to 6% of the gross proceeds in this offering. For additional information on the placement agents’ fees, see “Plan of Distribution” beginning on page S-6 of this prospectus supplement.
|
Investing
in our securities involves significant risks. See “Risk Factors” beginning on page S-3 of this prospectus supplement,
and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement
and the accompanying prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary
is a criminal offense.
Delivery
of the shares is expected to be made on or about February 4, 2021.
A.G.P.
Placement
Agent
The
date of this prospectus supplement is February 2, 2021.
TABLE
OF CONTENTS
PROSPECTUS
SUPPLEMENT
PROSPECTUS
ABOUT
THIS PROSPECTUS SUPPLEMENT
This
prospectus supplement and the accompanying prospectus are part of a “shelf” registration statement on Form S-3 (File
No. 333-239890) that was declared effective by the Securities and Exchange Commission, or the SEC, on July 23, 2020. Under
this “shelf” registration process, we may, from time to time, sell any combination of the securities described in
the accompanying prospectus in one or more offerings up to a total amount of $250,000,000. As of February 1, 2021, prior
to the consummation of this offering, we may be deemed to have sold $75,000,000 of securities under the foregoing “shelf”
registration statement.
This
document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and
also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into
this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus, which gives more general
information about the shares of our common stock and other securities we may offer from time to time under our “shelf”
registration statement, some of which does not apply to the common stock offered by this prospectus supplement.
Generally,
when we refer to this prospectus supplement, we are referring to both parts of this document combined together with all documents
incorporated by reference. To the extent there is a conflict between the information contained in this prospectus supplement,
on the one hand, and the information contained in the accompanying prospectus or any document incorporated by reference therein,
on the other hand, you should rely on the information in this prospectus supplement.
You
should read this prospectus supplement, the accompanying prospectus, and the documents incorporated by reference in this prospectus
supplement and the accompanying prospectus before making an investment decision. You should also read and consider the information
in the documents referred to in the sections of this prospectus supplement entitled “Where You Can Find More Information”
and “Incorporation of Certain Documents by Reference.”
You
should rely only on the information contained in or incorporated by reference into this prospectus supplement or contained in
or incorporated by reference into the accompanying prospectus to which we have referred you. We have not authorized anyone to
provide you with information that is different. If anyone provides you with different or inconsistent information, you should
not rely on it. The information contained in, or incorporated by reference into, this prospectus supplement and contained in,
or incorporated by reference into, the accompanying prospectus is accurate only as of the respective dates thereof, regardless
of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of securities.
We
are offering to sell, and are seeking offers to buy, the shares only in jurisdictions where such offers and sales are permitted.
The distribution of this prospectus supplement and the accompanying prospectus and the offering of the shares in certain states
or jurisdictions or to certain persons within such states and jurisdictions may be restricted by law. Persons outside the United
States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about and
observe any restrictions relating to the offering of the shares and the distribution of this prospectus supplement and the accompanying
prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not
be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus
supplement and the accompanying prospectus by any person in any state or jurisdiction in which it is unlawful for such person
to make such an offer or solicitation.
In
this prospectus supplement and the accompanying prospectus, unless otherwise indicated, the terms “Pluristem,” “we,”
“us” and “our” mean Pluristem Therapeutics Inc. and its wholly owned subsidiaries, Pluristem Ltd. and
Pluristem GmbH, as required by the context.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
The
statements contained in this prospectus supplement, the accompanying prospectus and the documents we incorporate by reference
herein or therein that are not historical facts are “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 and other federal securities laws. Such forward-looking statements may be identified
by, among other things, the use of forward-looking terminology such as “believes,” “intends,” “plans,”
“expects,” “may,” “will,” “should,” or “anticipates” or the negative
thereof or other variations thereon or comparable terminology, and similar expressions are intended to identify forward-looking
statements. Accordingly, forward-looking statements involve estimates, assumptions and are inherently subject to uncertainties
and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity, or
our achievements, or industry results, to be materially different from any future results, performance, levels of activity, achievements
or industry results, expressed or implied by such forward-looking statements. Such forward-looking statements include, among other
statements, statements regarding the following:
|
●
|
the
expected development and potential benefits from our products in treating various medical conditions;
|
|
●
|
our
entering into certain contracts with third parties;
|
|
●
|
the
prospects of entering into additional license agreements, or other forms of cooperation with other companies and medical institutions;
|
|
●
|
our
pre-clinical and clinical trials plans, including timing of initiation, enrollment and conclusion of trials;
|
|
●
|
achieving
regulatory approvals, including under accelerated paths;
|
|
●
|
receipt
of future funding from the Israel Innovation Authority, the European Union's Horizon 2020 program, as well as grants from
other independent third parties;
|
|
●
|
the
receipt of funds pursuant to our agreement with the European Investment Bank, and whether we will achieve the milestones necessary
to receive funds thereunder;
|
|
●
|
developing
capabilities for new clinical indications of placenta expanded, or PLX, cells and new products;
|
|
●
|
the
progress of our multinational regulated clinical trial program for the potential use of PLX cells in the treatment of patients
suffering from complications associated with the COVID-19 pandemic;
|
|
●
|
our
expectation to demonstrate a real-world impact and value from our pipeline, technology platform and commercial-scale manufacturing
capacity;
|
|
●
|
our
expectations regarding our short- and long-term capital requirements;
|
|
●
|
our
outlook for the coming months and future periods, including but not limited to our expectations regarding future revenue and
expenses;
|
|
●
|
information
with respect to any other plans and strategies for our business; and
|
|
●
|
our
expectation regarding the impact of the COVID-19 pandemic, including on our clinical trials and operations.
|
The
factors discussed herein, including those risks described under the heading “Risk Factors” herein, in the accompanying
prospectus and in the documents we incorporate by reference could cause actual results and developments to be materially different
from those expressed in or implied by such statements. In addition, historic results of scientific research, preclinical studies
and clinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions.
Also, historic results referred to this prospectus supplement, the accompanying prospectus and the documents we incorporate by
reference may be interpreted differently in light of additional research, clinical and preclinical trials results. Except as required
by law we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
PROSPECTUS
SUPPLEMENT SUMMARY
This
summary is qualified in its entirety by, and should be read together with, the more detailed information and financial statements
and related notes thereto appearing elsewhere or incorporated by reference in this prospectus supplement and the accompanying
prospectus. Before you decide to invest in our securities, you should read this entire prospectus supplement and the accompanying
prospectus carefully, including the sections titled “Risk Factors,” and our consolidated financial statements and
the related notes and other documents incorporated by reference herein and in the accompanying prospectus.
Our
Company
We
are a leading developer of placenta-based cell therapy product candidates for the treatment of multiple inflammatory and hematologic
conditions. Our operations are focused on the research, development, manufacturing, conducting clinical trials and business development
of cell therapeutics and related technologies.
PLX
cells are derived from a class of placental cells that are harvested from donated placenta at the time of full term healthy delivery
of a baby. The cells are grown using our proprietary three-dimensional expansion technology and can be administered to patients
off the-shelf, without blood or tissue matching prior to administration. PLX cells are believed to release a range of therapeutic
proteins in response to the patient’s condition such as inflammation, muscle trauma, hematological disorders and radiation
damage.
We
are currently enrolling patients in a multinational Phase III clinical study for muscle recovery following surgery for hip fracture
and two Phase II clinical studies in Acute Respiratory Distress Syndrome complicated by the COVID-19 coronavirus in the U.S.,
EU and Israel. We also expect to expand our COVID-19 program to Mexico following the announcement in December 2020 of our collaboration
with Innovare R&D.
In
addition, we are focusing on other clinical programs such as a Phase I clinical study for incomplete recovery following bone marrow
transplantation in the U.S. and Israel, an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study and acute radiation
syndrome under the FDA animal rule. We believe that each of these indications is a severe unmet medical need.
Our
manufacturing facility complies with the European, Japanese, Israeli, South Korean and the FDA’s current Good Manufacturing
Practice, or cGMP, requirements and has been inspected and approved by the European and Israeli regulators for production of PLX-PAD
for late stage trials. We have also granted manufacturer/importer authorization and cGMP Certification by Israel’s Ministry
of Health. If we obtain FDA and other regulatory approvals to market PLX cells, we expect to have in-house production capacity
to grow PLX cells in commercial quantities.
Our
goal is to make significant progress with our clinical pipeline and our clinical trials in order to ultimately bring innovative,
potent therapies to patients who need new treatment options. We expect to demonstrate a real-world impact and value from our pipeline,
technology platform and commercial-scale manufacturing capacity. Our business model for commercialization and revenue generation
includes, but is not limited to, direct sale of our products, partnerships, licensing deals, and joint ventures with pharmaceutical
companies.
Corporate
Information
We
were incorporated as a Nevada corporation in 2001. Pluristem Ltd. is our wholly owned subsidiary in Israel and Pluristem GmbH
is our wholly owned subsidiary in Germany. Our executive offices are located at MATAM Advanced Technology Park, Building No. 5,
Haifa, Israel, our telephone number is 011 972 74 7108600 and our website address is www.pluristem.com. This reference to our
website is an inactive textual reference only, and is not a hyperlink. The information on our website is not incorporated by reference
in this prospectus supplement and should not be considered to be part of this prospectus supplement. You should not consider the
contents of our website in making an investment decision with respect to the securities.
THE
OFFERING
Common
stock offered by us
|
|
4,761,905 shares of common stock.
|
|
|
|
Price
per share
|
|
$6.30
|
|
|
|
Common
stock to be outstanding immediately after this offering
|
|
31,529,267
shares of common stock.
|
|
|
|
Use
of proceeds
|
|
We
intend to use the net proceeds from the offering for working capital. See “Use of Proceeds.”
|
|
|
|
Risk
factors
|
|
An
investment in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-3 of this
prospectus supplement and on page 3 of the accompanying prospectus, as well as those risk factors that are incorporated by
reference in this prospectus supplement and the accompanying prospectus, for a discussion of factors to consider carefully
before deciding to purchase shares of our common stock.
|
|
|
|
Listing
on Nasdaq and TASE
|
|
Our common stock is listed on The Nasdaq Global Market under the
symbol “PSTI” and on TASE under the symbol “PSTI.”
|
Unless
otherwise indicated, all information in this prospectus supplement is based on 26,767,362 shares of common stock outstanding as
of January 31, 2021 and excludes as of such date:
|
●
|
39,835
shares of common stock issuable upon the exercise of outstanding stock options as of January 31, 2021 at a weighted-average
exercise price of $0.00001 per share;
|
|
●
|
3,894,520
shares of common stock reserved for future issuances under our equity compensation plan;
|
|
●
|
3,180,494
shares of common stock issuable upon the exercise of outstanding warrants as of January 31, 2021 at a weighted-average exercise
price of $8.68 per share; and
|
|
●
|
2,978,400
shares of common stock issuable upon the vesting of outstanding restricted stock and restricted stock units as of January 31, 2021.
|
Unless
otherwise indicated, all information in this prospectus supplement assumes no exercise of the outstanding options and warrants
listed above.
RISK
FACTORS
Investing
in our securities involves significant risks. You should carefully consider the risk factors below, in the accompanying prospectus
and in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, as well as
all of the information contained in this prospectus supplement, in the accompanying prospectus and the other documents incorporated
by reference herein or therein, before you decide to invest in our securities. Our business, prospects, financial condition and
results of operations may be materially and adversely affected as a result of any of such risks. The value of our securities could
decline as a result of any of these risks. You could lose all or part of your investment in our securities. The risks and uncertainties
we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently
deem immaterial may also affect our business, prospects, financial condition and results of operations.
Risks
Related to this Offering
Our
management will have broad discretion over the use of the proceeds we receive from this offering and may invest or spend the proceeds
of this offering in ways with which you may not agree or in ways which may not yield a significant return, if any.
We
intend to use the net proceeds from this offering for working capital. Our management will have significant flexibility in applying
the net proceeds of this offering. The actual amounts and timing of expenditures will vary significantly depending on a number
of factors, including the amount of cash used in our operations and our research and development efforts. We might apply these
proceeds in ways with which you do not agree, or in ways that do not yield a favorable return. If our management applies these
proceeds in a manner that does not yield a significant return, if any, on our investment of these net proceeds, it could compromise
our ability to pursue our growth strategy and adversely affect the market price of our common stock.
Future
sales of our shares may cause the prevailing market price of our shares to decrease.
We
have issued a substantial number of shares issued or issuable upon exercise of warrants and options to purchase our shares that
are eligible for, or may become eligible for, unrestricted resale, and additional warrants will be issued if this offering is
completed. Any sales or registration of such shares in the public market or otherwise could reduce the prevailing market price
for our shares, as well as make future sales of equity securities by us less attractive or even not feasible.
USE
OF PROCEEDS
We
estimate that our net proceeds from this offering will be approximately $28,070,000 at a public offering price of $6.30 per share
after deducting the estimated offering expenses that are payable by us.
We
intend to use the net proceeds from this offering for working capital.
The
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions,
which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures
depend on numerous factors, including the progress of development efforts, the ongoing status of and results from our ongoing
clinical trials and other studies and any unforeseen cash needs. As a result, our management will have broad discretion in applying
the net proceeds from this offering. Pending the application of the net proceeds, we intend to invest the net proceeds in bank
deposits or investment-grade, interest-bearing securities subject to any investment policies our investment committee may determine
from time to time.
CAPITALIZATION
The
following table sets forth our capitalization as of September 30, 2020:
|
●
|
on a pro forma basis
to give effect to the issuance of (i) 1,045,097 shares pursuant to our Open Market Sale AgreementSM; (ii) an aggregate
of 88,777 shares pursuant to awards under our equity compensation plan; (iii) an aggregate of 11,535 resulting from the exercise
of options by consultants; and (iv) an aggregate of 9,142 shares as a result of the exercise of certain warrants; and
|
|
●
|
on a pro forma as adjusted basis giving effect to the issuance and
sale of 4,761,905 shares in this offering at the public offering price of $6.30 per share, before deducting certain commissions
and discounts and other estimated offering expenses payable by us.
|
You
should read this table together with the information contained in this prospectus supplement and the accompanying prospectus and
the information incorporated by reference from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and
our Annual Report on Form 10-K for the year ended June 30, 2020, including the historical financial statements and related notes
included in each of those reports.
|
|
As of September 30, 2020
|
|
|
|
U.S. Dollars in thousands (unaudited)
|
|
|
|
Actual
|
|
|
Pro Forma
|
|
|
Pro Forma As Adjusted
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
|
Common stock, par value $0.00001 per share – authorized 60,000,000 shares; issued and outstanding 25,612,811 shares as of September 30, 2020; 26,767,362 shares issued and outstanding as of January 31, 2021; 31,529,267 on an as adjusted basis;
|
|
$
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Preferred stock, par value $0.00001 per share – authorized 1,000,000 shares, none issued
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional paid-in capital
|
|
|
337,593
|
|
|
|
349,585
|
|
|
|
377,655
|
|
Accumulated deficit
|
|
|
(288,645
|
)
|
|
|
(288,645
|
)
|
|
|
(288,645
|
)
|
Total stockholders’ equity
|
|
$
|
48,948
|
|
|
|
60,940
|
|
|
|
89,010
|
|
Unless
otherwise indicated, all information in this prospectus supplement is based on 26,767,362 shares of common stock outstanding as
of January 31, 2021 and excludes as of such date:
|
●
|
39,835
shares of common stock issuable upon the exercise of outstanding stock options as of January 31, 2021 at a weighted-average
exercise price of $0.00001 per share;
|
|
●
|
3,894,520
shares of common stock reserved for future issuances under our equity compensation plan;
|
|
●
|
3,180,494
shares of common stock issuable upon the exercise of outstanding warrants as of January 31, 2021 at a weighted-average exercise
price of $8.68 per share; and
|
|
●
|
2,978,400
shares of common stock issuable upon the vesting of outstanding restricted stock and restricted stock units as of January 31, 2021.
|
Unless
otherwise indicated, all information in this prospectus supplement assumes no exercise of the outstanding options and warrants
listed above.
DIVIDEND
POLICY
We
have never declared or paid any cash dividends on our common stock. We intend to retain any future earnings to finance the growth
and development of our business and do not anticipate paying any cash dividends in the foreseeable future. Any dividends paid
will be solely at the discretion of our board of directors.
PLAN
OF DISTRIBUTION
A.G.P./Alliance
Global Partners, which we refer to herein as the placement agent, has agreed to act as our exclusive placement agent in connection
with this offering subject to the terms and conditions of the placement agency agreement dated February 2, 2021. The placement
agent is not purchasing or selling any of the shares of our common stock offered by this prospectus supplement, nor is it required
to arrange the purchase or sale of any specific number or dollar amount of shares of our common stock, but has agreed to use its
reasonable best efforts to arrange for the sale of all of the shares of our common stock offered hereby. Therefore, we will enter
into a securities purchase agreement directly with investors in connection with this offering and we may not sell the entire amount
of shares of our common stock offered pursuant to this prospectus supplement. We will make offers only to a limited number of
qualified institutional buyers and accredited investors.
We
have agreed to indemnify the placement agent against specified liabilities, including liabilities under the Securities Act, and
to contribute to payments the placement agent may be required to make in respect thereof.
Fees
and Expenses
We
have agreed to pay the placement agent a placement agent’s fee equal to approximately $1,800,000, or 6%, of the aggregate
purchase price of the shares of our common stock sold in this offering. The following table shows the per share and total cash
placement agent’s fees we will pay to the placement agent in connection with the sale of the shares of our common stock
offered pursuant to this prospectus supplement and the accompanying prospectus, assuming the purchase of all of the shares offered
hereby on a best efforts basis:
|
|
Per Share
|
|
|
Total
|
|
Public offering price
|
|
$
|
6.30
|
|
|
$
|
30,000,000
|
|
Placement agent fees
|
|
$
|
0.378
|
|
|
$
|
1,800,000
|
|
Proceeds, before expenses, to us
|
|
$
|
5.922
|
|
|
$
|
28,200,000
|
|
We have also agreed to pay each of Maxim Group,
LLC, Ladenburg Thalmann & Co. Inc. and Dawson James a fee of $50,000 in connection with their acting as a financial advisor
with respect to the offering. We have also agreed to pay an Israeli financial advisor a fee of $180,000. We estimate the total
expenses payable by us for this offering, excluding the placement agent fees, financial advisor fees and expenses, will be approximately
$130,000.
The
placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be
underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply
with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities
Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and
sales of shares by the placement agent acting as principal. Under these rules and regulations, the placement agent:
|
●
|
may
not engage in any stabilization activity in connection with our securities; and
|
|
●
|
may
not bid for or purchase any of our securities or attempt to induce any person to purchase
any of our securities, other than as permitted under the Exchange Act, until it has completed
its participation in the distribution.
|
Listing
Our
shares of common stock are listed on The Nasdaq Global Market under the trading symbol “PSTI” and on the Tel Aviv
Stock Exchange under the trading symbol “PSTI.”
Restrictions
We have agreed, subject to certain exceptions,
not to sell or otherwise dispose of their respective shares of common stock or any securities convertible into or exchangeable
for common stock, for a period of at least 60 days from the completion of this offering; provided, however that we may conduct
sales under our existing Open Market Sale AgreementSM beginning 45 days after the closing of this offering.
Discretionary
Accounts
The
placement agent does not intend to confirm sales of the securities offered hereby to any accounts over which it has discretionary
authority.
Other
Activities and Relationships
The
placement agent and certain of its affiliates are full service financial institutions engaged in various activities, which may
include securities trading, commercial and investment banking, financial advisory, investment management, investment research,
principal investment, hedging, financing and brokerage activities. The placement agent and certain of its affiliates have, from
time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services
for us and our affiliates, for which they received or will receive customary fees and expenses.
In
the ordinary course of their various business activities, the placement agent and certain of its affiliates may make or hold a
broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments
(including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities
may involve securities and/or instruments issued by us and our affiliates. If the placement agent or its affiliates have a lending
relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies.
The placement agent and its affiliates may hedge such exposure by entering into transactions that consist of either the purchase
of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially
the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered
hereby. The placement agent and certain of its affiliates may also communicate independent investment recommendations, market
color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may
at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.
LEGAL
MATTERS
The
validity of the common stock offered hereby and certain other legal matters will be passed upon for us by Sullivan & Worcester
LLP, New York, New York. Gracin and Marlow, LLP, New York, New York, is acting as counsel to the placement agent in connection
with certain legal matters relating to this offering.
EXPERTS
The consolidated financial statements of Pluristem
appearing in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, and the effectiveness of the internal
control over financial reporting of Pluristem as of June 30, 2020, have been audited by Kost Forer Gabbay & Kasierer, a member
of Ernst & Young Global, independent registered public accounting firm, as set forth in their reports thereon, included therein,
and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon
such report given on the authority of such firm as experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available
to the public over the Internet at the SEC’s website at www.sec.gov. Copies of certain information filed by us with
the SEC are also available on our website at www.pluristem.com. Our website is not a part of this prospectus supplement
and is not incorporated by reference in this prospectus supplement. This reference to the websites is an inactive textual reference
only, and is not a hyperlink.
This
prospectus is part of a registration statement we filed with the SEC. This prospectus supplement and the accompanying prospectus
omit some information contained in the registration statement in accordance with SEC rules and regulations. You should review
the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and
the securities we are offering. Statements in this prospectus supplement and the accompanying prospectus concerning any document
we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive
and are qualified by reference to these filings. You should review the complete document to evaluate these statements. You can
obtain a copy of the registration statement from the SEC’s website.
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
We
are “incorporating by reference” certain documents we file with the SEC, which means that we can disclose important
information to you by referring you to those documents. The information in the documents incorporated by reference is considered
to be part of this prospectus supplement. Statements contained in documents that we file with the SEC and that are incorporated
by reference in this prospectus supplement will automatically update and supersede information contained in this prospectus, including
information in previously filed documents or reports that have been incorporated by reference in this prospectus supplement, to
the extent the new information differs from or is inconsistent with the old information.
We
have filed or may file the following documents with the SEC. These documents are incorporated herein by reference as of their
respective dates of filing:
|
(a)
|
Our
Annual Report on Form
10-K for the year ended June 30, 2020, as filed with the SEC on September 10, 2020;
|
|
(b)
|
Our
Quarterly Report on Form
10-Q for the quarter ended September 30, 2020, as filed with the SEC on November
5, 2020;
|
|
(c)
|
Our
Current Reports on Form 8-K filed with the SEC on July
1, 2020, July
16, 2020, July
21, 2020, August
10, 2020, August
27, 2020, September
15, 2020, October
7, 2020, November
18, 2020, December
9, 2020 and January 6, 2021; and
|
|
(d)
|
The
description of our common stock contained in the Registration Statement on Form
8-A filed on December 10, 2007, under the Exchange Act, including any amendment or
report filed or to be filed for the purpose of updating such description.
|
All
documents filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until all of the securities to which this
prospectus supplement relates has been sold or the offering is otherwise terminated, except in each case for information contained
in any such filing where we indicate that such information is being furnished and is not to be considered “filed”
under the Exchange Act, will be deemed to be incorporated by reference in this prospectus supplement and the accompanying prospectus
and to be a part hereof from the date of filing of such documents.
We
will provide a copy of the documents we incorporate by reference, at no cost, to any person who receives this prospectus supplement.
To request a copy of any or all of these documents, you should write or telephone us at MATAM Advanced Technology Park, Building
No. 5, Haifa, 3508409, Israel, Attention: Chen Franco-Yehuda.
PROSPECTUS
$250,000,000
Common Stock
Preferred Stock
Warrants
Units
We may from time
to time sell common stock, preferred stock and warrants to purchase common stock, and units of two or more of such securities,
in one or more offerings for an aggregate initial offering price of $250,000,000. We refer to the common stock, the preferred
stock, the warrants to purchase common stock and the units collectively as the securities. This prospectus describes the general
manner in which our securities may be offered using this prospectus. Other than in connection with the exercise of certain outstanding
warrants, we will specify in an accompanying prospectus supplement the terms of the securities to be offered and sold. We may
sell these securities to or through underwriters or dealers, directly to purchasers or through agents. We will set forth the names
of any underwriters, dealers or agents in an accompanying prospectus supplement. You should carefully read this prospectus
and any accompanying supplements before you decide to invest in any of these securities.
Our common stock
is traded on the Nasdaq Capital Market, or Nasdaq, under the symbol “PSTI” and on the Tel Aviv Stock Exchange, or
TASE, under the symbol “PSTI.” On July 14, 2020, the last reported sale price of our common stock on The Nasdaq Capital
Market was $8.40 per share.
Investing in
our securities involves risks. See “Risk Factors” on page 3 of this prospectus.
Neither the
Securities and Exchange Commission, or the SEC, nor any state securities commission has approved or disapproved of these securities
or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus
is July 23, 2020.
TABLE
OF CONTENTS
You should
rely only on the information contained in this prospectus, any prospectus supplement and the documents incorporated by reference
herein or therein, or to which we have referred you. We have not authorized anyone to provide you with different information.
If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus and any prospectus
supplement do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered by this prospectus
and any prospectus supplement in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer
or solicitation of an offer in such jurisdiction. You should not assume that the information contained in this prospectus, any
prospectus supplement or any document incorporated by reference is accurate as of any date other than the date indicated in the
applicable document.
Neither the delivery
of this prospectus nor any distribution of securities pursuant to this prospectus shall, under any circumstances, create any implication
that there has been no change in the information set forth or incorporated by reference into this prospectus or in our affairs
since the date of this prospectus. Our business, financial condition, results of operations and prospects may have changed since
that date.
Our name and logo
and the names of our products are our trademarks or registered trademarks. Unless the context otherwise requires, references in
this prospectus to “Pluristem,” “we,” “us,” and “our” refer to Pluristem Therapeutics
Inc. and its subsidiaries as required by the context.
ABOUT
THIS PROSPECTUS
This prospectus
is part of a registration statement that we filed with the SEC using a “shelf” registration process. Under this shelf
registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or
more offerings up to a total dollar amount of $250,000,000. This prospectus describes the securities we may offer and the general
manner in which our securities may be offered by this prospectus. Each time we sell securities (other than in connection with
the exercise of certain outstanding warrants), we will provide a prospectus supplement that will contain specific information
about the terms of that offering. We may also add, update or change in the prospectus supplement any of the information contained
in this prospectus. To the extent there is a conflict between the information contained in this prospectus and the prospectus
supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents
is inconsistent with a statement in another document having a later date - for example, a document incorporated by reference
in this prospectus or any prospectus supplement - the statement in the document having the later date modifies or supersedes
the earlier statement.
OUR
COMPANY
This summary
highlights information contained in the documents incorporated herein by reference. Before making an investment decision, you
should read the entire prospectus, and our other filings with the SEC, including those filings incorporated herein by reference,
carefully, including the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.”
We are a leading developer of placenta-based
cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Our operations
are focused on the research, development, manufacturing, conducting clinical trials, business development and marketing of cell
therapeutics and related technologies.
We are currently enrolling
patients in two Phase III studies: one for critical limb ischemia, or CLI, and another for muscle recovery following surgery for
hip fracture. In addition, we are focusing on other indications such as acute radiation syndrome, incomplete recovery following
bone marrow transplantation, Chronic Graft Versus Host Disease (cGVHD) and intermittent claudication. We have treated several
patients in Israel and in the U.S., under a compassionate use program, suffering from severe acute respiratory failure and inflammatory
complications associated with COVID-19. In May 2020, the U.S. Food and Drug Administration, or the FDA, cleared our IND application
for the Phase II study of our PLX cells in the treatment of severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome,
or ARDS. On June 11, 2020, we announced the activation of clinical sites and commencement of enrollment in our Phase II FDA study
of PLX cells for the treatment of severe COVID-19 complicated by ARDS. We believe that each of these indications is a severe unmet
medical need.
PLX cells are derived
from a class of placental cells that are harvested from donated placenta at the time of full term healthy delivery of a baby.
PLX cell products require no tissue matching prior to administration. They are produced using our proprietary three-dimensional
expansion technology. Our manufacturing facility complies with the European, Japanese, Israeli, South Korean and the FDA’s
current Good Manufacturing Practice requirements and has been inspected and approved by the European and Israeli regulators for
production of PLX-PAD for late stage trials. We have also granted manufacturer/importer authorization and Good Manufacturing Practice
Certification by Israel’s Ministry of Health. If we obtain FDA and other regulatory approvals to market PLX cells, we expect
to have in-house production capacity to grow PLX cells in commercial quantities.
Our goal is to make significant
progress with our clinical pipeline and our clinical trials in order to ultimately bring innovative, potent therapies to patients
who need new treatment options. We expect to demonstrate a real-world impact and value from our pipeline, technology platform
and commercial-scale manufacturing capacity. Our business model for commercialization and revenue generation includes, but is
not limited to, direct sale of our products, partnerships, licensing deals, and joint ventures with pharmaceutical companies.
We aim to shorten the
time to commercialization of our product candidates by leveraging unique accelerated regulatory pathways that exist in the United
States, Europe and other territories to bring innovative products that address life-threatening diseases to the market efficiently.
We believe that these accelerated pathways create substantial opportunities for us and for the cell therapy industry as a whole.
We
were incorporated as a Nevada corporation in 2001. We have a wholly owned subsidiary in Israel called Pluristem Ltd. and
a wholly owned subsidiary in Germany called Pluristem GmbH. Our executive offices are located at MATAM Advanced Technology
Park, Building No. 5, Haifa, Israel, our telephone number is 011 972 74 710 8600 and our website address is www.pluristem.com.
This reference to our website is an inactive textual reference only, and is not a hyperlink. The information on our website is
not incorporated by reference in this prospectus and should not be considered to be part of this prospectus. You should not consider
the contents of our website in making an investment decision with respect to the securities.
RISK
FACTORS
An investment
in our securities involves significant risks. You should carefully consider the risk factors below as well as risk factors contained
in any prospectus supplement and in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended
June 30, 2019 as well as all of the information contained in this prospectus, any prospectus supplement and the other documents
incorporated by reference herein or therein, before you decide to invest in our securities. Our business, prospects, financial
condition and results of operations may be materially and adversely affected as a result of any of such risks. The
value of our securities could decline as a result of any of these risks. You could lose all or part of your investment
in our securities. The risks and uncertainties we have described are not the only ones we face. Additional risks and
uncertainties not presently known to us or that we currently deem immaterial may also affect our business, prospects, financial
condition and results of operations.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING INFORMATION
The statements
contained in this prospectus, any prospectus supplement and the documents we incorporate by reference herein or therein that are
not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Such forward-looking statements may be identified by, among other things, the use
of forward-looking terminology such as “believes,” “intends,” “plans,” “expects,”
“may,” “will,” “should,” or “anticipates” or the negative thereof or other variations
thereon or comparable terminology, and similar expressions are intended to identify forward-looking statements. We
remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other
factors and involve known and unknown risks that could cause the actual results, performance, levels of activity, or our achievements,
or industry results, to be materially different from any future results, performance, levels of activity, achievements or industry
results, expressed or implied by such forward-looking statements. The factors discussed herein, including those risks described
under the heading “Risk Factors” herein and in the documents we incorporate by reference, as well as those discussed
elsewhere in this prospectus and any prospectus supplement, could cause actual results and developments to be materially different
from those expressed in or implied by such statements. In addition, historic results of scientific research, clinical and preclinical
trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions. Also, historic
results referred to this prospectus, any prospectus supplement and the documents we incorporate by reference may be interpreted
differently in light of additional research, clinical and preclinical trials results. Except as required by law we undertake no
obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
USE
OF PROCEEDS
Unless we otherwise
indicate in an applicable prospectus supplement, we currently intend to use the net proceeds from the sale of the securities for
research and product development activities, clinical trial activities, manufacturing for clinical trials and for preparing our
product candidates for commercialization, marketing and business development, investment in capital equipment and for working
capital and other general corporate purposes.
We may set forth
additional information on the use of net proceeds from the sale of securities we offer under this prospectus in a prospectus supplement
relating to the specific offering. Pending the application of the net proceeds, we intend to invest any proceeds in a variety
of capital preservation instruments such as bank deposits or investment-grade, interest-bearing securities subject to any investment
policies our investment committee may determine from time to time.
THE
SECURITIES WE MAY OFFER
The descriptions
of the securities contained in this prospectus, together with any applicable prospectus supplement, summarize the material terms
and provisions of the various types of securities that we may offer. We will describe in any applicable prospectus supplement
relating to any securities the particular terms of the securities offered by that prospectus supplement. If we so indicate in
any applicable prospectus supplement, the terms of the securities may differ from the terms we have summarized below. We may also
include in any prospectus supplement information, where applicable, about material U.S. federal income tax consequences relating
to the securities, and the securities exchange or market, if any, on which the securities will be listed.
We may sell from
time to time, in one or more offerings, one or more of the following securities:
|
●
|
warrants
to purchase common stock; and
|
|
●
|
units
of two or more of the securities mentioned above.
|
The total initial
offering price of all securities that we may issue in these offerings will not exceed $250,000,000.
DESCRIPTION
OF CAPITAL STOCK
The following
summary is a description of the material terms of our share capital. We encourage you to read our Certificate of Incorporation,
as amended, and Amended and Restated By-laws which have been filed with the SEC, as well as the applicable provisions of the Nevada
Revised Statutes.
As of July 16,
2020, our authorized capital stock consists of 60,000,000 shares of common stock, after the approval of the increase of our
authorized capital stock by our stockholders at the annual stockholders meeting held on June 29, 2020, of which there were 18,673,173
shares outstanding as of March 31, 2020 and 25,492,712 shares outstanding as of June 30, 2020, and 1,000,000 shares of “blank
check” preferred stock, none of which are outstanding. The following statements set forth the material terms of our capital
stock; however, reference is made to the more detailed provisions of, and these statements are qualified in their entirety by
reference to, our Articles of Incorporation and Bylaws, copies of which are referenced as exhibits herein, and the provisions
of Nevada General Corporation Law. Except for our ability to issue additional securities, including preferred stock
with terms that may be determined at a later date by our Board, there are no provisions in our Articles of Incorporation or Bylaws
that would delay, defer or prevent a change in our control.
Common Stock
Except as otherwise
required by applicable law and subject to the preferential rights of any outstanding preferred stock, all voting rights are vested
in and exercised by the holders of common stock with each share of our common stock being entitled to one vote. In
the event of liquidation, holders of the common stock are entitled to share ratably in the distribution of assets remaining after
payment of liabilities, if any. Holders of the common stock have no cumulative voting rights and no preemptive or other
rights to subscribe for shares. Holders of common stock are entitled to such dividends as may be declared by the Board of Directors
out of funds legally available therefor.
Blank Check Preferred Stock
Our Board of Directors
is empowered, without further action by stockholders, to issue from time to time one or more series of preferred stock, with such
designations, rights, preferences and limitations as the Board may determine by resolution. The rights, preferences and limitations
of separate series of preferred stock may differ with respect to such matters among such series as may be determined by the Board,
including, without limitation, the rate of dividends, method and nature of payment of dividends, terms of redemption, amounts
payable on liquidation, sinking fund provisions (if any), conversion rights (if any) and voting rights. Certain issuances of preferred
stock may have the effect of delaying or preventing a change in control of our company that some stockholders may believe is not
in their interest.
Transfer Agent
American Stock
Transfer and Trust Company, LLC is the registrar and transfer agent for our common shares. Their address is 6201 15th
Avenue, 2nd Floor, Brooklyn, NY 11219, telephone: (718) 921-8261, (800) 937-5449.
Nevada Anti-Takeover Law
Nevada revised
statutes sections 78.378 to 78.3793 provide state regulation over the acquisition of a controlling interest in certain Nevada
corporations unless the articles of incorporation or bylaws of the corporation provide that the provisions of these sections do
not apply. This statute currently does not apply to our Company because in order to be applicable we would have to
have as shareholders a specified number of Nevada residents and we would have to do business in Nevada directly or through an
affiliate.
DESCRIPTION
OF WARRANTS
The following
description, together with the additional information we may include in any applicable prospectus supplement, summarizes the material
terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates.
While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular terms
of any series of warrants (and any securities issuable upon exercise of such warrants) in more detail in the applicable prospectus
supplement. If we so indicate in a prospectus supplement, the terms of any warrants offered under that prospectus supplement may
differ from the terms we describe below. Specific warrant agreements will contain additional important terms and provisions and
will be incorporated by reference as an exhibit to the registration statement.
General
We may issue warrants
for the purchase of common stock in one or more series. We may issue warrants independently or together with common stock, and
the warrants may be attached to or separate from the common stock.
We will evidence
each series of warrants by warrant certificates that we will issue under a separate agreement or by warrant agreements that we
will enter into directly with the purchasers of the warrants. If we evidence warrants by warrant certificates, we will enter into
a warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent, if any, in the applicable
prospectus supplement relating to a particular series of warrants.
We will describe
in the applicable prospectus supplement the terms of the series of warrants, including:
|
●
|
the
offering price and aggregate number of warrants offered;
|
|
●
|
the
currency for which the warrants may be purchased or exercised;
|
|
●
|
if
applicable, the terms of the common stock with which the warrants are issued and the
number of warrants issued with such common stock;
|
|
●
|
if
applicable, the date on and after which the warrants and the related common stock will
be separately transferable;
|
|
●
|
the
number of shares of common stock or other securities purchasable upon the exercise of
one warrant and the price at which these shares may be purchased upon such exercise;
|
|
●
|
the
manner in which the warrants may be exercised, which may include by cashless exercise;
|
|
●
|
the
effect of any merger, consolidation, sale or other disposition of our business on the
warrant agreement and the warrants;
|
|
●
|
the
terms of any rights to redeem or call the warrants;
|
|
●
|
any
provisions for changes to or adjustments in the exercise price or number of shares of
common stock issuable upon exercise of the warrants;
|
|
●
|
the
dates on which the right to exercise the warrants will commence and expire;
|
|
●
|
the
manner in which the warrant agreement and warrants may be modified;
|
|
●
|
the
material United States federal income tax consequences of holding or exercising the warrants;
|
|
●
|
the
terms of the common stock issuable upon exercise of the warrants; and
|
|
●
|
any
other specific terms, preferences, rights or limitations of or restrictions on the warrants.
|
Before exercising
their warrants, holders of warrants will not have any of the rights of holders of the common stock purchasable upon such exercise,
including the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise voting
rights, if any.
Exercise of Warrants
Each warrant will
entitle the holder to purchase the number of shares of common stock that we specify in the applicable prospectus supplement at
the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus
supplement, holders of the warrants may exercise the warrants at any time up to 5:00 P.M., Eastern U.S. time, on the expiration
date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised
warrants will become void.
Holders of the
warrants may exercise the warrants by delivering to the warrant agent or us the warrant certificate or warrant agreement representing
the warrants to be exercised together with specified information, and by paying the required amount to the warrant agent or us
in immediately available funds, as provided in the applicable prospectus supplement. We will set forth on the reverse side of
the warrant certificate or in the warrant agreement and in the applicable prospectus supplement the information that the holder
of the warrant will be required to deliver to the warrant agent or us in connection with such exercise.
Upon receipt of
the required payment and the warrant certificate or the warrant agreement, as applicable, properly completed and duly executed
at the corporate trust office of the warrant agent, if any, at our offices or at any other office indicated in the applicable
prospectus supplement, we will issue and deliver the common stock or other securities purchasable upon such exercise. If fewer
than all of the warrants represented by the warrant certificate or warrant agreement are exercised, then we will issue a new warrant
certificate or warrant agreement for the remaining amount of warrants.
Enforceability of Rights by Holders
of Warrants
If we appoint
a warrant agent, any warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any
obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant
agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under
the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise,
or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of
any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise
of, its warrants.
Outstanding Warrants
The shares of
common stock registered under the registration statement of which this prospectus is a part include 2,470,466 shares of common
stock issuable upon exercise of warrants that were issued under our registration statement on Form S-3 declared effective on June
30, 2017 (Registration No. 333-218916). Such warrants were issued on April 8, 2019, have an exercise price of $7.00 per share
and expire on April 8, 2024.
In addition, the
shares of common stock registered under the registration statement of which this prospectus is a part include 762,028 shares of
common stock issuable upon exercise of warrants that were issued under our registration statement on Form S-3 declared effective
on October 30, 2014 (Registration No. 333-199303). Such warrants were issued on January 25, 2017, have an exercise price of $14.00
per share and expire on July 20, 2022.
No prospectus
supplement will be delivered in connection with the issuance of these shares of common stock pursuant to the exercise of such
warrants.
DESCRIPTION
OF UNITS
We may issue,
in one or more series, units consisting of common stock, preferred stock and/or warrants for the purchase of common stock and/or
preferred stock, in any combination. While the terms we have summarized below will apply generally to any units that we
may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable
prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described
below.
We will file as
exhibits to a prospectus supplement, or will incorporate by reference from reports that we file with the SEC, the form of unit
agreement that describes the terms of the series of units we are offering, and any supplemental agreements, before the issuance
of the related series of units. The following summaries of material terms and provisions of the units are subject to, and
qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements applicable
to a particular series of units. We urge you to read the applicable prospectus supplement related to the particular series
of units that we may offer under this prospectus and the complete unit agreement and any supplemental agreements that contain
the terms of the units.
Each unit will
be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a
unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is
issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time
before a specified date.
We will describe
in the applicable prospectus supplement the terms of the series of units, including:
|
●
|
the
designation and terms of the units, including whether and under what circumstances the
securities comprising the units may be held or transferred separately; and
|
|
●
|
any
provisions for the issuance, payment, settlement, transfer or exchange of the units or
the securities comprising the units.
|
The provisions
described in this section, as well as those described under “Description of Capital Stock” and “Description
of Warrants” will apply to each unit and to any common stock, preferred stock or warrant included in each unit, respectively.
We may issue units
in such amounts and in such distinct series as we determine.
PLAN
OF DISTRIBUTION
We may sell the
securities being offered hereby in one or more of the following ways from time to time:
|
●
|
through
agents to the public or to investors;
|
|
●
|
to
one or more underwriters or distributors for resale to the public or to investors;
|
|
●
|
in
“at the market offerings,” within the meaning of Rule 415(a)(4) of the Securities
Act ;
|
|
●
|
directly
to investors in privately negotiated transactions;
|
|
●
|
directly
to a purchaser pursuant to what is known as an “equity line of credit” as
described below;
|
|
●
|
through
a combination of these methods of sale; or
|
|
●
|
upon
exercise of outstanding warrants.
|
The
securities that we distribute by any of these methods may be sold, in one or more transactions, at:
|
●
|
a
fixed price or prices, which may be changed;
|
|
●
|
market
prices prevailing at the time of sale;
|
|
●
|
prices
related to prevailing market prices; or
|
The
accompanying prospectus supplement will describe the terms of the offering of our securities, including:
|
●
|
the
name or names of any agents or underwriters;
|
|
●
|
any
securities exchange or market on which the common stock may be listed;
|
|
●
|
the
purchase price and commission, if any, to be paid in connection with the sale of the
securities being offered and the proceeds we will receive from the sale;
|
|
●
|
any
over-allotment options pursuant to which underwriters may purchase additional securities
from us;
|
|
●
|
any
underwriting discounts or agency fees and other items constituting underwriters’
or agents’ compensation;
|
|
●
|
any
public offering price; and
|
|
●
|
any
discounts or concessions allowed or reallowed or paid to dealers.
|
If underwriters
are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in
one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined
at the time of the sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set
forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented
by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated
to purchase all the securities offered by the prospectus supplement. We may change from time to time the public offering price
and any discounts or concessions allowed or reallowed or paid to dealers.
If we use a dealer
in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities
to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the
dealer at the time of resale. The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.
We may sell the
securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale
of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement
states otherwise, any agent will act on a best-efforts basis for the period of its appointment.
We may also sell
securities pursuant to an “equity line of credit”. In such event, we will enter into a common stock purchase agreement
with the purchaser to be named therein, which will be described in a Current Report on Form 8-K that we will file with the SEC.
In that Form 8-K, we will describe the total amount of securities that we may require the purchaser to purchase under the purchase
agreement and the other terms of purchase, and any rights that the purchaser is granted to purchase securities from us. In addition
to our issuance of shares of common stock to the equity line purchaser pursuant to the purchase agreement, this prospectus (and
the applicable prospectus supplement or post-effective amendment) also covers the resale of those shares from time to time by
the equity line purchaser to the public. The equity line purchaser will be considered an “underwriter” within the
meaning of Section 2(a)(11) of the Securities Act. Its resales may be effected through a number of methods, including without
limitation, ordinary brokerage transactions and transactions in which the broker solicits purchasers and block trades in which
the broker or dealer so engaged will attempt to sell the shares as agent, but may position and resell a portion of the block as
principal to facilitate the transaction. The equity line purchaser will be bound by various anti-manipulation rules
of the SEC and may not, for example, engage in any stabilization activity in connection with its resales of our securities and
may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than
as permitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act.
We may sell our
securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale
of our common stock, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus
supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment.
We may provide
underwriters and agents with indemnification against civil liabilities related to offerings pursuant to this prospectus, including
liabilities under the Securities Act, or contribution with respect to payments that the underwriters or agents may make with respect
to these liabilities. Underwriters and agents may engage in transactions with, or perform services for, us in the ordinary course
of business. We will describe such relationships in the prospectus supplement naming the underwriter or agent and the nature of
any such relationship.
Rules of the SEC
may limit the ability of any underwriters to bid for or purchase securities before the distribution of the shares of common stock
is completed. However, underwriters may engage in the following activities in accordance with the rules:
|
●
|
Stabilizing
transactions — Underwriters may make bids or purchases for the purpose
of pegging, fixing or maintaining the price of the shares, so long as stabilizing bids
do not exceed a specified maximum.
|
|
●
|
Options
to purchase additional stock and syndicate covering transactions — Underwriters
may sell more shares of our common stock than the number of shares that they have committed
to purchase in any underwritten offering. This creates a short position for the underwriters.
This short position may involve either “covered” short sales or “naked”
short sales. Covered short sales are short sales made in an amount not greater than the
underwriters’ option to purchase additional shares in any underwritten offering.
The underwriters may close out any covered short position either by exercising their
option or by purchasing shares in the open market. To determine how they will close the
covered short position, the underwriters will consider, among other things, the price
of shares available for purchase in the open market, as compared to the price at which
they may purchase shares through their option. Naked short sales are short sales in excess
of the option. The underwriters must close out any naked position by purchasing shares
in the open market. A naked short position is more likely to be created if the underwriters
are concerned that, in the open market after pricing, there may be downward pressure
on the price of the shares that could adversely affect investors who purchase shares
in the offering.
|
|
●
|
Penalty
bids — If underwriters purchase shares in the open market in a stabilizing
transaction or syndicate covering transaction, they may reclaim a selling concession
from other underwriters and selling group members who sold those shares as part of the
offering.
|
Similar to other
purchase transactions, an underwriter’s purchases to cover the syndicate short sales or to stabilize the market price of
our common stock may have the effect of raising or maintaining the market price of our common stock or preventing or mitigating
a decline in the market price of our common stock. As a result, the price of the shares of our common stock may be higher than
the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price
of shares if it discourages resales of the shares.
If commenced,
the underwriters may discontinue any of these activities at any time.
Our common stock
is traded on the Nasdaq Capital Market and on the Tel Aviv Stock Exchange. One or more underwriters may make a market in our common
stock, but the underwriters will not be obligated to do so and may discontinue market making at any time without notice. We cannot
give any assurance as to liquidity of the trading market for our common stock.
Any underwriters
who are qualified market makers on the Nasdaq Capital Market may engage in passive market making transactions in that market in
the common stock in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering,
before the commencement of offers or sales of the common stock. Passive market makers must comply with applicable volume and price
limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price
not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker’s
bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded.
LEGAL
MATTERS
Sullivan &
Worcester LLP, New York, New York, passed upon the validity of the securities offered hereby. Additional legal matters may be
passed upon for any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement.
EXPERTS
The consolidated
financial statements of Pluristem Therapeutics Inc. appearing in our Annual Report on Form 10-K for the fiscal year ended June
30, 2019 and the effectiveness of the internal control over financial reporting of Pluristem Therapeutics Inc. as of June 30,
2019, have been audited by Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, independent registered public
accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated
financial statements are incorporated herein by reference in reliance upon such reports given on the authority of such firm as
experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
We have filed a registration statement
on Form S-3 under the Securities Act with the SEC with respect to the shares of our common stock, preferred stock, warrants and
units offered through this prospectus. This prospectus is filed as a part of that registration statement and does not contain
all of the information contained in the registration statement and exhibits. We refer you to our registration statement and each
exhibit attached to it for a more complete description of matters involving us, and the statements we have made in this prospectus
are qualified in their entirety by reference to these additional materials.
We are subject to the reporting and information
requirements of the Exchange Act and as a result file periodic reports and other information with the SEC. You can review our
SEC filings and the registration statement by accessing the SEC’s internet site at http://www.sec.gov. We maintain a corporate
website at https://www.pluristem.com. Information contained on, or that can be accessed through, our website does not constitute
a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
INCORPORATION
OF DOCUMENTS BY REFERENCE
We are “incorporating
by reference” certain documents we file with the SEC, which means that we can disclose important information to you by referring
you to those documents. The information in the documents incorporated by reference is considered to be part of this prospectus.
Statements contained in documents that we file with the SEC and that are incorporated by reference in this prospectus will automatically
update and supersede information contained in this prospectus, including information in previously filed documents or reports
that have been incorporated by reference in this prospectus, to the extent the new information differs from or is inconsistent
with the old information
We have filed
or may file the following documents with the SEC. These documents are incorporated herein by reference as of their respective
dates of filing:
|
(a)
|
Our Annual Report on Form
10-K for the year ended June 30, 2019 filed with the SEC on September 12, 2019;
|
|
(b)
|
Our Quarterly Reports on Form 10-Q for the quarters ended
September
30, 2019, December
31, 2019 and March
31, 2020, as filed with the SEC on November 7, 2019, February 6, 2020 and May 11,
2020, respectively;
|
|
(c)
|
Our Current Reports on Form 8-K filed with the SEC on July
2, 2019, July
25, 2019, August
12, 2019, March
3, 2020, March
12, 2020, March
26, 2020, March
30, 2020, April
7, 2020, April
13, 2020, April
24, 2020, April
30, 2020, May
5, 2020, May
8, 2020, May
14, 2020, June
11, 2020 and July
1, 2020; and
|
|
(d)
|
The description of our common stock contained in the Registration
Statement on Form
8-A filed on December 10, 2007, under the Exchange Act, including any amendment or
report filed or to be filed for the purpose of updating such description.
|
All documents filed by us pursuant to Section 13(a),
13(c), 14 or 15(d) of the Exchange Act (1) after the date of the filing of the registration statement of which this prospectus
forms a part and prior to its effectiveness and (2) until all of the securities to which this prospectus relates has been
sold or the offering is otherwise terminated, except in each case for information contained in any such filing where we indicate
that such information is being furnished and is not to be considered “filed” under the Exchange Act, will be deemed
to be incorporated by reference in this prospectus and any accompanying prospectus supplement and to be a part hereof from the
date of filing of such documents.
We will provide
a copy of the documents we incorporate by reference, at no cost, to any person who receives this prospectus. To request a copy
of any or all of these documents, you should write or telephone us at MATAM Advanced Technology Park, Building No. 5, Haifa, 3508409,
Israel, Attention: Chen Yehuda-Franco.
4,761,905
Shares of Common Stock
PROSPECTUS
SUPPLEMENT
A.G.P.
Placement
Agent
February
2, 2021
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Apr 2023 to Apr 2024